Navigation Links
Positive Clinical Study Results for BSP's HyperQ Technology

TEL-AVIV, Israel, November 14, 2011 /PRNewswire/ --

BSP Biological Signal Processing Ltd. (BSP) (TASE: BSP), which develops and manufactures products for the non-invasive, accurate diagnosis of Coronary Artery Disease (CAD), recently announced the successful completion of a comprehensive clinical research study evaluating the performance of the company's HyperQ technology in diagnosing CAD. An article describing the study and its results was accepted for publication in the prestigious American Journal of Cardiology.

The study recruited 996 patients and compared the clinical performance of HyperQ vs. conventional ECG for the detection of Coronary Artery Disease (CAD), using nuclear imaging as the gold standard. The study was conducted in two major medical centers in Israel - Assuta Medical Center and Sheba Medical Center, and was headed by Dr. Tali Sharir and Prof. Pierre Chouraqui.  The major finding reported by the researchers is a 30% improvement in the sensitivity of the HyperQ analysis in the detection of CAD when compared to conventional stress ECG. HyperQ analysis also had a lower false alarm rate compared to conventional stress ECG.

"This comprehensive study significantly deepens clinical knowledge accumulated so far by our company and substantiates the evidence that HyperQ improves the ability to diagnose ischemic heart disease," says Nissim Greisas, CEO of BSP.  He added, "We believe that the results of this study will have a major impact on the decision of cardiologists to clinically implement the use of HyperQ products in their routine workup for diagnosing and assessing ischemic heart disease."

The results of this study were also recently presented, together with additional HyperQ related clinical evidence, at a meeting and hearing of the Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) in the US. The MEDCAC meeting on November 9th was convened in order to consider and make recommendations on the use of new ECG signal analysis technologies to detect CAD, and regarding their inclusion in the coverage policies.  MEDCAC is an advisory committee, commissioned by to CMS (Centers for Medicare & Medicaid Services) - the organization responsible for the determination of the services and medical products that will be reimbursed by Medicare and Medicaid, also heavily weighing in on the coverage policies of private insurers in the US. The MEDCAC committee concluded its discussions with a recommendation encouraging the CMS to include new signal analysis technologies, that are FDA cleared and have shown sufficient clinical evidence, in the coverage policies for cardiac care and diagnosis.

"Appearing before MEDCAC committee is an important milestone in the process of obtaining reimbursement for our products in the U.S.," says Dr. Amir Beker, Chairman of BSP, who presented at the hearing. He added, "This endeavor is also backed by a HyperQ large-scale clinical study in three leading US medical centers, The Cleveland Clinic, University of Virginia medical center and Minneapolis Heart Institute Foundation, to collect clinical and economic data in support of BSP's reimbursement campaign in the US".

About Biological Signal Processing Ltd.  

Founded in 2000, BSP develops the most accurate stress ECG equipment for diagnosing Coronary Artery Disease (CAD) for men and women. HyperQ, BSP's proprietary signal processing technology, focuses on a brand new component of the ECG signal, significantly improving the accuracy of the stress ECG test and making HyperQ technology- the new standard for the early detection of coronary artery disease.  BSP is a public company, traded on the Tel Aviv Stock Exchange since 2006 (TASE: BSP). The company's headquarters are located in Tel Aviv, Israel with offices in Boston, US.


For further information, please contact , +972-3-647-4840


SOURCE BSP - Biological Signal Processing Ltd
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
2. Unigene Announces Positive Top-Line Results of Phase 2 Oral PTH Study for the Treatment of Osteoporosis in Postmenopausal Women
3. Boston Scientific Platinum Chromium ION™ Stent Demonstrates Positive Outcomes in PERSEUS Clinical Program
4. Regado Biosciences, Inc. Presents Positive Efficacy and Safety Substudy Data from the Phase 2b RADAR Trial for the REG1 Anticoagulation System at the Transcatheter Cardiovascular Therapeutics (TCT) Symposium 2011
5. NORTHWEST BIO Announces Positive Third Quarter Progress
6. Otonomy Presents Positive New Findings From Phase 1b Study of OTO-104 in Menieres Disease at International Conference
7. Elevation Pharmaceuticals Presents Positive Phase 2a Results in COPD Patients at the European Respiratory Society Annual Congress
8. Positive Phase 2 Trial Results from Neuroendocrine Tumor Cohort Presented at CIRSE
9. Ardea Biosciences Announces Positive End-of-Phase 2 Meetings with FDA for Lesinurad
10. Jennerex Reports Positive Mechanistic Proof-of-Concept Clinical Trial Results Using JX-594 to Treat Metastatic Melanoma
11. Intarcia Presents Positive Phase 2 48-week Results From ITCA 650 Study at the American Diabetes Association 71st Scientific Sessions
Post Your Comments:
(Date:11/24/2015)... ... November 24, 2015 , ... International Society for ... of the premier annual events for pharmaceutical manufacturing: 2015 Annual Meeting. The conference ... ISPE hosted the largest number of attendees in more than a decade. ...
(Date:11/24/2015)... ... 2015 , ... This fall, global software solutions leader SAP and AdVenture Capital ... and pitch their BIG ideas to improve health and wellness in their schools. , ... win the title of SAP's Teen Innovator, an all-expenses paid trip to Super Bowl ...
(Date:11/24/2015)...  Tikcro Technologies Ltd. (OTCQB: TIKRF) today announced that its Annual General ... a.m. Israel time, at the law offices of ... 36 th Floor, Tel Aviv, Israel . ... Izhak Tamir to the Board of Directors; , election ... , approval of an amendment to certain terms of options granted to ...
(Date:11/24/2015)... ... ... InSphero AG, the leading supplier of easy-to-use solutions for production, culture, and ... as Chief Operating Officer. , Having joined InSphero in November 2013 as ... promoted to Head of InSphero Diagnostics in 2014. There she has built up ...
Breaking Biology Technology:
(Date:11/10/2015)... , Nov. 10, 2015 ... behavioral biometrics that helps to identify and verify ... Signature is considered as the secure and accurate ... identification of a particular individual because each individual,s ... accurate results especially when dynamic signature of an ...
(Date:11/4/2015)... November 4, 2015 --> ... report published by Transparency Market Research "Home Security Solutions Market ... Forecast 2015 - 2022", the global home security solutions market is ... by 2022. The market is estimated to expand at ... 2015 to 2022. Rising security needs among customers at ...
(Date:10/29/2015)... JOLLA, Calif. , Oct. 29, 2015  The ... a new report titled, "DNA Synthesis and Biosecurity: Lessons ... well the Department of Health and Human Services guidance ... issued in 2010. --> ... but it also has the potential to pose unique ...
Breaking Biology News(10 mins):